Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine + G-CSF + low-dose cytarabine + aclarubicin in refractory/relapsed AML
ChiCTR-OPC-16010166Phase 4Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in acute myeloid leukemia (AML), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Complete remission rate. Started Dec 2016; status: recruiting.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OPC-16010166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16010166.